September 2026, Vol 16, No 5
The visibility of pharmacy benefit managers (PBMs) and the need for control and oversight of their policies against patients access to needed care is growing exponentially at both state and national levels. Read More ›
In oncology practice management, claim denials are more than an administrative inconvenience. Read More ›
At the front desk, the first moments of a patient interaction can shape both the patient experience and the safety of the clinical environment. Read More ›
We are more than 6 months into Medicare’s radiation oncology coding overhaul, and many community radiation oncology practices report negative impacts to their bottom line and the ability to give patients proper treatment. Read More ›
Oncology practice managers are responsible for far more than scheduling and staffing. Read More ›
On July 10, 2026, the FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with enfortumab vedotin-ejfv (Padcev), as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer (MIBC). Read More ›
On July 14, 2026, the FDA granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors harboring a RET gene fusion, as detected by an FDA-approved test, after progression on prior systemic therapy or when no satisfactory alternative treatment options are available. Read More ›
On July 14, 2026, the FDA approved gedatolisib (Revtorpyk) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after progression on or after at least 1 line of endocrine therapy in the metastatic setting. Read More ›
On July 22, 2026, the FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who have received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI). Read More ›
A crackling sound in the ear of a loving grandfather, a young college woman brushing off troubling symptoms, and a rising football star about to achieve his lifelong dream—all blind-sided by rare diseases that either masqueraded as cancer or made them vulnerable to it. Read More ›